PI3K

Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that catalyze the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) to generate the second messenger phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P₃). The production of PI(3,4,5)P₃ facilitates the recruitment and activation of pleckstrin homology (PH) domain–containing proteins at the plasma membrane, thereby initiating downstream signaling cascades essential for cellular proliferation, survival, and migration.

PI3Ks are divided into three major classes, among which Class I PI3Ks are most prominently implicated in cancer biology. Class I enzymes comprise four distinct catalytic isoforms: PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ.

Class IA PI3Ks, the subclass most commonly associated with oncogenic signaling, function as heterodimeric lipid kinases composed of a catalytic p110 subunit (p110α, p110β, or p110δ, encoded by PIK3CA, PIK3CB, and PIK3CD, respectively) and a regulatory p85 subunit.

The PI3K signaling pathway plays a central role in diverse biological processes, including cell cycle progression, cellular growth, survival, actin cytoskeletal rearrangement, migration, and intracellular vesicular trafficking.

Frequently Asked Questions
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate phosphatidylinositol lipids to regulate cell growth, survival, metabolism, and immune signaling. PI3K activation leads to downstream AKT and mTOR pathway signaling. Aberrant PI3K signaling is frequently observed in cancer due to PIK3CA mutations, PTEN loss, or receptor tyrosine kinase activation.
Class I PI3Ks include four catalytic isoforms: PI3Kα (PIK3CA) PI3Kβ (PIK3CB) PI3Kδ (PIK3CD) PI3Kγ (PIK3CG) PI3Kα and β are broadly expressed, while PI3Kδ and γ are enriched in leukocytes and play critical roles in immune regulation. Isoform selectivity is an important consideration in drug development due to toxicity and immune effects.
PI3K inhibitors can be classified as: Pan-PI3K inhibitors Isoform-selective inhibitors (α, β, δ, γ) Dual PI3K/mTOR inhibitors Irreversible inhibitors Selectivity influences therapeutic window and toxicity profile.
While PI3K inhibitors block upstream lipid kinase activity, mTOR inhibitors act downstream at the level of mTORC1 or mTORC2. Dual PI3K/mTOR inhibitors target both nodes of the pathway and may achieve broader pathway suppression.

Items 351-369 of 369

  • PI3Kα-IN-20
    Cat. No.
    A79882

    PI3Kα-IN-20

    PI3Kα-IN-20 is a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα). It effectively disrupts the PI3K signaling pathway, leading to the modulation of cellular functions such as growth, proliferation, and survival. This compound is valuable for research applications focused on cancer biology, metabolic disorders, and other conditions associated with aberrant PI3Kα activity.

    Out of stock

    All 3 sizes
  • PI3Kδ/γ-IN-2
    Cat. No.
    A79883

    PI3Kδ/γ-IN-2

    PI3Kδ/γ-IN-2 is a potent dual inhibitor of phosphoinositide 3-kinase delta (PI3Kδ) and gamma (PI3Kγ), demonstrating IC50 values of 1 nM and 4.3 nM, respectively. With favorable oral bioavailability, this compound shows promise in the treatment of B-cell malignancies, making it a valuable tool for research in cancer biology and therapeutic development targeting the PI3K signaling pathway.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3K-IN-26
    Cat. No.
    A79886

    PI3K-IN-26

    PI3K-IN-26 is a potent inhibitor of phosphoinositide 3-kinase (PI3K), exhibiting an IC50 of 36 nM in SU-DHL-6 cells. This compound is useful in research focused on the PI3K signaling pathway, which plays a critical role in cell growth, proliferation, and survival. The inhibition of PI3K by PI3K-IN-26 allows for the investigation of its effects on cancer cell metabolism and identification of potential therapeutic targets.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3K-IN-10
    Cat. No.
    A79887

    PI3K-IN-10

    PI3K-IN-10 is a potent pan-PI3K inhibitor derived from benzimidazole. This compound selectively targets the phosphoinositide 3-kinase (PI3K) pathway, demonstrating significant inhibitory activity across various PI3K isoforms. Its key biological activity makes it a valuable tool for investigating PI3K-related signaling mechanisms and potential therapeutic applications in cancer and metabolic disorders.

    Out of stock

    All 3 sizes
  • PI3Kδ-IN-23
    Cat. No.
    A79888

    PI3Kδ-IN-23

    PI3Kδ-IN-23 is a highly selective inhibitor of the PI3Kδ isoform, exhibiting an exceptional binding affinity with an IC50 value of 0.27 nM. This compound forms covalent bonds with the Lys779 residue on PI3Kδ, effectively blocking its activity. Its potent inhibition profile makes PI3Kδ-IN-23 a valuable tool for cancer research, particularly in studies focused on therapeutic strategies targeting PI3K signaling pathways.

    Out of stock

    All 3 sizes
  • PI3Kα-IN-1
    Cat. No.
    A79890

    PI3Kα-IN-1

    PI3Kα-IN-1 is a potent inhibitor of the phosphoinositide 3-kinase alpha (PI3Kα) with an IC50 value of less than 0.5 nM. Additionally, it exhibits inhibitory activity against mTOR with an IC50 of 104 nM. This compound is valuable for studying the PI3K/mTOR signaling pathway, which is implicated in various diseases, including cancer and metabolic disorders. Research applications include evaluating the effects of PI3Kα inhibition on cell proliferation, survival, and signaling.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3Kδ-IN-26
    Cat. No.
    A79891

    PI3Kδ-IN-26

    PI3Kδ-IN-26 is a selective and orally active inhibitor of the PI3Kδ isoform, exhibiting an IC50 of 14 nM. This compound has demonstrated significant efficacy in attenuating inflammatory responses in house dust mite-induced chronic asthma models in mice. Due to its potent anti-inflammatory properties, PI3Kδ-IN-26 is a valuable tool for research into inflammatory, autoimmune, and hyperproliferative diseases.

    Out of stock

    All 3 sizes
  • LTURM 36
    Cat. No.
    A79892

    LTURM 36

    LTURM 36 is a potent inhibitor of phosphoinositide 3-kinase (PI3K), exhibiting IC50 values of 0.64 μM for PI3Kδ and 5.0 μM for PI3Kβ. This compound serves as a valuable tool in cancer research by modulating PI3K signaling pathways, which are frequently implicated in tumorigenesis and cancer progression. Its selective inhibition profile positions LTURM 36 as an important reagent for studying the roles of PI3K isoforms in various cancer types.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3Kα-IN-24
    Cat. No.
    A79893

    PI3Kα-IN-24

    PI3Kα-IN-24 is a potent inhibitor of PI3Kα, exhibiting an IC50 of 0.025 μM. This compound effectively suppresses phosphorylated Akt at serine 473, demonstrating significant impact in cellular signaling pathways. It is a valuable tool for cancer research, allowing for the exploration of PI3Kα-mediated mechanisms and therapeutic strategies.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3Kα-IN-17
    Cat. No.
    A79894

    PI3Kα-IN-17

    PI3Kα-IN-17 is a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα), a critical enzyme in the PI3K signaling pathway. This compound demonstrates potent inhibitory activity, making it valuable for research focused on cancer biology and other diseases linked to dysregulated PI3Kα activity. It can be utilized to explore the role of PI3Kα in cancer cell proliferation, survival, and metabolism.

    Out of stock

    All 3 sizes
  • PI3K-IN-54
    Cat. No.
    A79896

    PI3K-IN-54

    PI3K-IN-54 is a potent pan-PI3K inhibitor that targets the p110α, p110β, and p110δ isoforms with IC50 values of 0.22 nM, 1.4 nM, and 0.38 nM, respectively. This compound is valuable for investigating the role of PI3K signaling in various cancers. Its ability to inhibit multiple isoforms makes PI3K-IN-54 a useful tool for studying cancer progression and therapy resistance.

    1 mg
    $45.00
    5 mg
    $115.00
    All 6 sizes
  • GNE-293
    Cat. No.
    A79897

    GNE-293

    GNE-293 is a selective inhibitor of phosphoinositide 3-kinase delta (PI3Kδ), demonstrating an IC50 of 4.38 nM. This compound exhibits favorable pharmacokinetic properties, making it suitable for in vitro and in vivo studies. GNE-293 is particularly relevant for research into asthma, rheumatoid arthritis, and various inflammatory disorders.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • AS2541019
    Cat. No.
    A79898

    AS2541019

    AS2541019 is a selective inhibitor of the PI3Kδ (p110δ) isoform, effectively targeting the phosphoinositide 3-kinase pathway. This compound demonstrates notable inhibitory effects on B cell activation and proliferation, making it useful for evaluating immune responses. Additionally, AS2541019 has been shown to suppress antibody production in xenograft models, contributing to its potential applications in immunological research.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3K-IN-11
    Cat. No.
    A79899

    PI3K-IN-11

    PI3K-IN-11 is a selective inhibitor of phosphoinositide 3-kinases (PI3K), targeting PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ with IC50 values of 6.4, 13, 8, and 11 nM, respectively, while showing significantly lower affinity for mTOR (IC50=2.9 μM). This compound demonstrates over 420-fold selectivity for PI3K in a comprehensive panel of 20 lipid and protein kinases. In PTEN-negative U87MG cells, PI3K-IN-11 effectively inhibits the phosphorylation of Akt and S6 kinase (S6K) at concentrations between 0.03 and 1 μg/mL. Additionally, it has shown potential in reducing tumor growth in U87MG mouse xenograft models at doses ranging from 2.5 to 10 mg/kg, making it a valuable tool for cancer research.

    1 mg
    $155.00
    5 mg
    $395.00
    All 3 sizes
  • AM-0687
    Cat. No.
    A79900

    AM-0687

    AM-0687 is a selective inhibitor of phosphoinositide 3-kinase delta (PI3Kδ), exhibiting an IC50 of 2.9 nM. This compound effectively reduces levels of IgG and IgM specific antibodies and inhibits the proliferation of human B cells induced by anti-IgM/CD40L with an IC50 of 0.8 nM. Additionally, AM-0687 decreases AKT phosphorylation with an IC50 of 0.7 nM, demonstrating its potential as an anti-inflammatory agent in various research applications.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • GSK2636771 methyl
    Cat. No.
    A79901

    GSK2636771 methyl

    GSK2636771 methyl is a selective inhibitor of PI3Kβ, a key lipid kinase involved in cellular signaling pathways regulating growth and survival. This compound is primarily utilized in cancer research, where it can be combined with other agents, such as VT-464, to explore potential therapeutic strategies. Its role in modulating PI3Kβ activity aids in the investigation of cancer metabolism and treatment resistance mechanisms.

    Out of stock

    All 3 sizes
  • mTOR inhibitor-25
    Cat. No.
    A79903

    mTOR inhibitor-25

    mTOR inhibitor-25 is a selective inhibitor of the mechanistic target of rapamycin (mTOR), demonstrating significant anticancer activity. It exhibits strong inhibitory effects on mTOR while having a comparatively weaker impact on phosphoinositide 3-kinase (PI3K). This compound is valuable for research applications focused on various cancers, including leukemia, skin cancer, breast cancer, lung cancer, and colon cancer, and has shown excellent efficacy in cell proliferation assays.

    1 mg
    $120.00
    5 mg
    $285.00
    All 7 sizes
  • NIBR-17
    Cat. No.
    A79904

    NIBR-17

    NIBR-17 is a pan-class I PI3K inhibitor that targets phosphoinositide 3-kinases, key regulators in various signaling pathways. This compound demonstrates significant antitumor activity by effectively inhibiting cell proliferation and survival in cancer models. It is suitable for research applications focused on cancer biology and drug discovery targeting the PI3K/Akt signaling pathway.

    1 mg
    $30.00
    5 mg
    $90.00
    All 5 sizes
  • PF-06862309
    Cat. No.
    A98853

    PF-06862309

    PF-06862309 is a phosphate ester prodrug of PF-06843195, which serves as a highly selective inhibitor of PI3Kα. Upon exposure to alkaline phosphatase, PF-06862309 is hydrolyzed to release the active form, PF-06843195. This compound is particularly useful for studying breast cancer models characterized by estrogen receptor positivity, HER2 negativity, and PIK3CA mutations, providing insights into targeted therapeutic strategies in this context.

    25 mg
    $1,655.00
    50 mg
    $2,115.00
    All 3 sizes

Items 351-369 of 369

Added to your cart

View Cart Checkout

    Loading...